203 related articles for article (PubMed ID: 22088206)
41. Does continuous use of metformin throughout pregnancy improve pregnancy outcomes in women with polycystic ovarian syndrome?
Nawaz FH; Khalid R; Naru T; Rizvi J
J Obstet Gynaecol Res; 2008 Oct; 34(5):832-7. PubMed ID: 18834342
[TBL] [Abstract][Full Text] [Related]
42. Neonatal outcome in polycystic ovarian syndrome patients treated with metformin during pregnancy.
Kovo M; Weissman A; Gur D; Levran D; Rotmensch S; Glezerman M
J Matern Fetal Neonatal Med; 2006 Jul; 19(7):415-9. PubMed ID: 16923696
[TBL] [Abstract][Full Text] [Related]
43. Anti-Mullerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome.
Das M; Gillott DJ; Saridogan E; Djahanbakhch O
Hum Reprod; 2008 Sep; 23(9):2122-6. PubMed ID: 18550512
[TBL] [Abstract][Full Text] [Related]
44. Medical therapy in women with polycystic ovarian syndrome before and during pregnancy and lactation.
Goldenberg N; Glueck C
Minerva Ginecol; 2008 Feb; 60(1):63-75. PubMed ID: 18277353
[TBL] [Abstract][Full Text] [Related]
45. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):93-8. PubMed ID: 16360262
[TBL] [Abstract][Full Text] [Related]
46. Metformin influence on hormone levels at birth, in PCOS mothers and their newborns.
Carlsen SM; Vanky E
Hum Reprod; 2010 Mar; 25(3):786-90. PubMed ID: 20023292
[TBL] [Abstract][Full Text] [Related]
47. [Metformin, an efficacious drug in the treatment of polycystic ovary syndrome].
Hahn S; Quadbeck B; Elsenbruch S; Gärtner R; Finke R; Mann K; Janssen OE
Dtsch Med Wochenschr; 2004 May; 129(19):1059-64. PubMed ID: 15136950
[TBL] [Abstract][Full Text] [Related]
48. Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism.
Romualdi D; De Marinis L; Campagna G; Proto C; Lanzone A; Guido M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):562-7. PubMed ID: 18248643
[TBL] [Abstract][Full Text] [Related]
49. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin.
Maciel GA; Soares Júnior JM; Alves da Motta EL; Abi Haidar M; de Lima GR; Baracat EC
Fertil Steril; 2004 Feb; 81(2):355-60. PubMed ID: 14967373
[TBL] [Abstract][Full Text] [Related]
50. Serum antimüllerian hormone in response to dietary management and/or physical exercise in overweight/obese women with polycystic ovary syndrome: secondary analysis of a randomized controlled trial.
Nybacka Å; Carlström K; Fabri F; Hellström PM; Hirschberg AL
Fertil Steril; 2013 Oct; 100(4):1096-102. PubMed ID: 23876536
[TBL] [Abstract][Full Text] [Related]
51. CAG repeat polymorphism of androgen receptor gene and X-chromosome inactivation in daughters of women with polycystic ovary syndrome (PCOS): relationship with endocrine and metabolic parameters.
Echiburú B; Pérez-Bravo F; Maliqueo M; Ladrón de Guevara A; Gálvez C; Crisosto N; Sir-Petermann T
Gynecol Endocrinol; 2012 Jul; 28(7):516-20. PubMed ID: 22724574
[TBL] [Abstract][Full Text] [Related]
52. Metformin therapy increases insulin-like growth factor binding protein-1 in hyperinsulinemic women with polycystic ovary syndrome.
Pawelczyk L; Spaczynski RZ; Banaszewska B; Duleba AJ
Eur J Obstet Gynecol Reprod Biol; 2004 Apr; 113(2):209-13. PubMed ID: 15063962
[TBL] [Abstract][Full Text] [Related]
53. Effects of chronic hyperandrogenism and/or administered central nervous system insulin on ovarian manifestation and gonadotropin and steroid secretion.
Allon MA; Leach RE; Dunbar J; Diamond MP
Fertil Steril; 2005 Apr; 83 Suppl 1():1319-26. PubMed ID: 15831308
[TBL] [Abstract][Full Text] [Related]
54. Serum anti-Mullerian hormone levels in the main phenotypes of polycystic ovary syndrome.
Sahmay S; Atakul N; Oncul M; Tuten A; Aydogan B; Seyisoglu H
Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):157-61. PubMed ID: 23806449
[TBL] [Abstract][Full Text] [Related]
55. The effect of follicular antimullerian hormone levels of non-obese, non-hyperandrogenemic polycystic ovary syndrome patients on assisted reproduction outcome.
Yilmaz N; Uygur D; Dogan M; Ozgu E; Salman B; Mollamahmutoglu L
Gynecol Endocrinol; 2012 Mar; 28(3):162-5. PubMed ID: 22103791
[TBL] [Abstract][Full Text] [Related]
56. Impact of metformin on anti-Müllerian hormone in women with polycystic ovary syndrome: a secondary analysis of a randomized controlled trial.
Madsen HN; Lauszus FF; Trolle B; Ingerslev HJ; Tørring N
Acta Obstet Gynecol Scand; 2015 May; 94(5):547-51. PubMed ID: 25736975
[TBL] [Abstract][Full Text] [Related]
57. Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome.
Sir-Petermann T; Codner E; Pérez V; Echiburú B; Maliqueo M; Ladrón de Guevara A; Preisler J; Crisosto N; Sánchez F; Cassorla F; Bhasin S
J Clin Endocrinol Metab; 2009 Jun; 94(6):1923-30. PubMed ID: 19223518
[TBL] [Abstract][Full Text] [Related]
58. Insulin resistance and hyperandrogenism have no substantive association with birth weight in adolescents with polycystic ovary syndrome.
Fulghesu AM; Manca R; Loi S; Fruzzetti F
Fertil Steril; 2015 Mar; 103(3):808-14. PubMed ID: 25637475
[TBL] [Abstract][Full Text] [Related]
59. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.
Kolodziejczyk B; Duleba AJ; Spaczynski RZ; Pawelczyk L
Fertil Steril; 2000 Jun; 73(6):1149-54. PubMed ID: 10856473
[TBL] [Abstract][Full Text] [Related]
60. Influence of oral contraceptives on anthropomorphometric, endocrine, and metabolic profiles of anovulatory polycystic ovary syndrome patients.
Mes-Krowinkel MG; Louwers YV; Mulders AG; de Jong FH; Fauser BC; Laven JS
Fertil Steril; 2014 Jun; 101(6):1757-65.e1. PubMed ID: 24680368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
